At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
PF-06741086biological
Likely dose
PF-06741086 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, NON-CONTROLLED MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF A SINGLE SUBCUTANEOUS DOSE OF PF-06741086 IN CHINESE ADULT PARTICIPANTS WITH SEVERE HEMOPHILIA
In Brief
A Phase 1 clinical trial evaluating PF-06741086 for Severe Hemophilia. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This Phase 1 study will be a single-arm, open-label, non-randomized, non-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086 in Chinese adult participants with severe hemophilia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Hemophilia
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartApr 2021
First PostedMay 2021
Primary CompletionAug 2021
TodayJul 2026
First PostedMay 7, 2021
Enrollment StartApr 16, 2021
Primary CompletionAug 10, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.2 years ago
Interventions
PF-06741086biological
single dose SC injection of 300 mg PF-06741086